Roche Introduces Automated Test for Hepatitis D Virus
The fully automated, high-throughput assay for Hepatitis D virus RNA is available on cobas 5800/6800/8800 systems in CE mark-accepting countries.
The fully automated, high-throughput assay for Hepatitis D virus RNA is available on cobas 5800/6800/8800 systems in CE mark-accepting countries.
The facility will support the clinical validation of diagnostic kits that provide results via a mobile app without the need for laboratory processing.
New research indicates that standard and modified two-tiered testing algorithms fail to detect infection in up to 78% of patients during the early stages of the disease.
A field-deployable test demonstrates high sensitivity in identifying low-level infections that traditional methods miss, potentially supporting elimination efforts.
The rapid RT-PCR assay runs on the FINDER platform, establishing it as a molecular point-of-care platform with multifunctional capabilities.
The PCR test detects 11 bacterial, viral, and parasitic pathogens from a stool sample in approximately 74 minutes.
Research identifies how circulating tumor DNA can inform personalized treatment and surveillance strategies.